Cargando…
Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236677/ https://www.ncbi.nlm.nih.gov/pubmed/32460208 http://dx.doi.org/10.1016/j.mehy.2020.109856 |
_version_ | 1783536191326388224 |
---|---|
author | Gigante, Antonio Aquili, Alberto Farinelli, Luca Caraffa, Alessandro Ronconi, Gianpaolo Enrica Gallenga, Carla Tetè, Giulia Kritas, Spyros K. Conti, Pio |
author_facet | Gigante, Antonio Aquili, Alberto Farinelli, Luca Caraffa, Alessandro Ronconi, Gianpaolo Enrica Gallenga, Carla Tetè, Giulia Kritas, Spyros K. Conti, Pio |
author_sort | Gigante, Antonio |
collection | PubMed |
description | A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune cells implicated in the pathogenesis of viral infections, where they mediate inflammation. Microbes, including virus, activate MCs through TLR releasing chemical pro-inflammatory compounds and cytokines. Although, in biomedical literature there are only few reports on MCs activation by SARS-CoV-2 infection. The production of pro-inflammatory cytokines by MC viral activation leads to increase pulmonary inflammation and fibrosis. Sodium Chromo-Glycate (SCG) described as a MC stabilizer, prevents the release of inflammatory chemical compounds, improve mouse survival and respiratory pathological changes in lung viral infection and suppresses inflammation. Furthermore, palmitoylethanolamide (PEA) a nuclear factor agonist, an endogenous fatty acid amide, which exerts a variety of biological effects, related to chronic inflammation and pain, is involved also in MCs homeostasis with an inhibitory and protective effect on the respiratory tract during viral infections. Here, we hypothesize for the first time, that SCG and/or PEA suppress MC activation and pro-inflammatory mediators release, playing an anti-inflammatory therapeutic role in the inflamed lung of patients with COVID-19. |
format | Online Article Text |
id | pubmed-7236677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72366772020-05-19 Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 Gigante, Antonio Aquili, Alberto Farinelli, Luca Caraffa, Alessandro Ronconi, Gianpaolo Enrica Gallenga, Carla Tetè, Giulia Kritas, Spyros K. Conti, Pio Med Hypotheses Article A novel human coronavirus SARS‐CoV‐2 (also referred to as CoV-19) that emerged in late 2019 causes Covid-19 disease a respiratory tract infection which provokes about 4 million deaths per year. Unfortunately, to date, there is no specific antiviral treatment for COVID-19. Mast cells (MCs) are immune cells implicated in the pathogenesis of viral infections, where they mediate inflammation. Microbes, including virus, activate MCs through TLR releasing chemical pro-inflammatory compounds and cytokines. Although, in biomedical literature there are only few reports on MCs activation by SARS-CoV-2 infection. The production of pro-inflammatory cytokines by MC viral activation leads to increase pulmonary inflammation and fibrosis. Sodium Chromo-Glycate (SCG) described as a MC stabilizer, prevents the release of inflammatory chemical compounds, improve mouse survival and respiratory pathological changes in lung viral infection and suppresses inflammation. Furthermore, palmitoylethanolamide (PEA) a nuclear factor agonist, an endogenous fatty acid amide, which exerts a variety of biological effects, related to chronic inflammation and pain, is involved also in MCs homeostasis with an inhibitory and protective effect on the respiratory tract during viral infections. Here, we hypothesize for the first time, that SCG and/or PEA suppress MC activation and pro-inflammatory mediators release, playing an anti-inflammatory therapeutic role in the inflamed lung of patients with COVID-19. Elsevier Ltd. 2020-10 2020-05-19 /pmc/articles/PMC7236677/ /pubmed/32460208 http://dx.doi.org/10.1016/j.mehy.2020.109856 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Gigante, Antonio Aquili, Alberto Farinelli, Luca Caraffa, Alessandro Ronconi, Gianpaolo Enrica Gallenga, Carla Tetè, Giulia Kritas, Spyros K. Conti, Pio Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title | Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title_full | Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title_fullStr | Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title_full_unstemmed | Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title_short | Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19 |
title_sort | sodium chromo-glycate and palmitoylethanolamide: a possible strategy to treat mast cell-induced lung inflammation in covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236677/ https://www.ncbi.nlm.nih.gov/pubmed/32460208 http://dx.doi.org/10.1016/j.mehy.2020.109856 |
work_keys_str_mv | AT giganteantonio sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT aquilialberto sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT farinelliluca sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT caraffaalessandro sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT ronconigianpaolo sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT enricagallengacarla sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT tetegiulia sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT kritasspyrosk sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 AT contipio sodiumchromoglycateandpalmitoylethanolamideapossiblestrategytotreatmastcellinducedlunginflammationincovid19 |